Loading
A phase 3 trial of Bicalutamide, Buserelin, Flutamide, Goserelin / leuprolide, Leuprolide and Nilutamide in Prostate cancer, run by NCIC Clinical Trials Group, completed.
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer is a phase 3 interventional study registered as NCT00003653 by NCIC Clinical Trials Group, with 1386 participants recorded, started 1999-01-05 and reaching its primary completion in 2010-10-04. Interventions recorded: bicalutamide, buserelin, cyproterone acetate, flutamide, goserelin, leuprolide acetate, nilutamide. Conditions recorded: Prostate Cancer.
Linked to the drug Nilutamide because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Nilutamide, Buserelin, Flutamide, Bicalutamide and the tag pipeline.
Shares Nilutamide, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag pipeline.
Shares Buserelin, Flutamide, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
Shares Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
Shares Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.